[144] Natera, Inc. SEC Filing

Rhea-AI Filing Summary

Natera, Inc. (NTRA) Form 144 notice shows proposed and recent sales of common stock by Solomon Moshkevich. The filer plans to sell 3,000 shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $499,864.50 based on the filing. The issuer has 137,248,106 shares outstanding per the form. The seller acquired the 3,000 shares being offered as restricted stock and performance shares between 12/20/2024 and 01/26/2025 (lots of 818, 1,648, 292 and 242 shares). In the past three months the same person sold a total of 9,372 shares across five transactions (dates from 07/01/2025 to 08/14/2025) generating gross proceeds of approximately $1,482,439 as listed on the form. The filing includes standard Rule 144 attestations but does not provide a filer CIK or contact details in the visible tables.

Positive

• Transparency: The form discloses acquisition dates and nature of award (restricted stock and performance shares) for the securities being sold.
• Routine compliance: Broker and planned sale date are provided, enabling market transparency for the proposed sale.

Negative

• Missing contact identifiers: The provided extract does not include a filer CIK or submission contact details in the visible tables.
• Concentration of recent sales: The filer sold 9,372 shares in the past three months, which could be notable for monitoring insider activity despite being small versus total shares outstanding.

Insights

Financial Analyst

TL;DR: Routine insider sale consistent with recent acquisitions; transaction size is small relative to outstanding shares.

The filing documents a proposed sale of 3,000 common shares and recent disposals totaling 9,372 shares by the same individual. The proposed sale's aggregate market value of $499,864.50 and the 9,372 shares previously sold represent a trivial fraction of the issuer's 137,248,106 shares outstanding (well under 0.01%). Acquisitions disclosed on the form indicate the shares to be sold were awarded as restricted stock and performance shares between December 2024 and January 2025, suggesting insider liquidity rather than external purchase. No earnings or operational data are provided, so the filing's material impact on company valuation or operations appears limited and procedural.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 mechanics; document includes standard certifications but lacks some contact identifiers in the visible tables.

The notice includes the required details about the class of securities, broker name, number of shares, acquisition dates, and nature of acquisition (restricted stock and performance shares). The signer represents no undisclosed material adverse information per the form. The visible tables do not show a filer CIK or submission contact details, which may be present elsewhere in the filing system but are not included in the provided extract. From a governance perspective, these are routine insider sales disclosures with no red flags in the presented data.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3000	499864.50	137248106	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/26/2025	Restricted Stock	ISSUER			1648	01/26/2025	Not Applicable
Common	01/20/2025	Restricted Stock	ISSUER			292	01/20/2025	Not Applicable
Common	12/20/2024	Performance Shares	ISSUER			818	12/20/2024	Not Applicable
Common	01/21/2025	Restricted Stock	ISSUER			242	01/21/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	08/14/2025	875	136027.22
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	08/01/2025	3000	398657.40
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	07/28/2025	2206	308417.11
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	07/21/2025	291	40533.39
SOLOMON MOSHKEVICH 13011 McCallen Pass Building A Suite 100 Austin TX 78753	Common	07/01/2025	3000	500304.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the NTRA Form 144 disclose about the proposed sale?

The form shows a proposed sale of 3,000 common shares via Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $499,864.50.

How many shares has the insider sold recently according to the filing?

The filing lists five sales from 07/01/2025 to 08/14/2025 totaling 9,372 shares with combined gross proceeds of about $1,482,439.

How were the shares being offered acquired?

The shares were acquired as restricted stock and performance shares between 12/20/2024 and 01/26/2025, in lots of 818, 1,648, 292 and 242 shares.

What is the issuer's share count reported on the form?

The form reports 137,248,106 shares outstanding for the issuer.

Does the filing indicate any undisclosed material information by the seller?

By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed, as stated on the form.